This lack of robust correlation was also reported during the first phase II clinical trial of palbociclib in ALM patients, whereby the authors concluded “neither the genetic status nor the protein expression level of CDK4, CCND1, or CDKN2A was significantly associated with clinical response to palbociclib” [8]. This evidence concerns the gene CDK4 and acral lentiginous melanoma.